R adiofrequency catheter ablation (RFCA) has emerged as an effective and curative treatment option for atrial fibrillation (AF) and its use is increasing exponentially. 1 However, substantial number of patients experience arrhythmia recurrence, especially during a transient time after AF ablation defined as the blanking period. 2-5 Several hypotheses may potentially explain this early recurrence, including local and systemic inflammation 3,4 ; however, the mechanism for early recurrence has not been fully elucidated.
dysfunction and LV diastolic dysfunction, and whether this consequence influences early recurrence of AF after RFCA. We registered this prospective study as KCT0000030 at Clinical Research Information Service, Korea Centers for Disease Control and Prevention (http://cris.cdc.go.kr).
Methods

Study Population
From September 2010 to September 2011, we consecutively enrolled 136 patients who underwent RFCA for paroxysmal AF (PAF; n=73) and persistent AF (PeAF; n=63). The control group consisted of 34 patients undergoing RFCA for supraventricular tachycardia. PAF or PeAF was defined according to the most recent guideline of the Heart Rhythm Society and European Cardiac Arrhythmia Society. 2 Attempting to control for intrinsic limitations of beat-to-beat variations caused by AF, we included only subjects who had sinus rhythm for at least 24 hours before the examination. Then, subjects with AF at the time of enrollment were conducted direct current cardioversion and then monitored by continuous electrocardiography. Other exclusion criteria were significant coronary artery disease (>50% fixed stenosis), the presence of visible thrombi in left atrium (LA) by transesophageal echocardiography, previous AF ablation or cardiac surgery, aortic aneurysm or dissection, cardiomyopathy, more than mild valvular disease, congenital heart disease, an acute cerebrovascular event within the preceding 3 months, any major trauma or surgery within the preceding 3 months, hyperthyroidism, uncontrolled hypertension, malignancy, connective tissue disease, and any acute or chronic inflammatory diseases. All antiarrhythmic drugs were discontinued at least 5 half-lives before examination. Amiodarone was discontinued at least 8 weeks earlier. All patients were on continuous anticoagulation therapy with a target international normalized ratio of 2 to 3. Each participant signed an informed consent form before the study, which was approved by the Human Subjects Review Committee of Korea University Hospital.
Study Design
In all subjects enrolled, a 2-dimensional (2D) transthoracic echocardiography with Doppler study was conducted just before and at 1 day, 1 month, and 3 months after RFCA. In all patients with AF, we measured the index of microvascular resistance (IMR), which is a well-known index for specific and quantitative assessment of coronary microcirculatory resistance to assess coronary microvascular function. [8] [9] [10] [11] Immediately before and after RFCA, the IMR was measured, and blood samples were obtained from the coronary sinus for analyses of high-sensitivity C-reactive protein (hs-CRP), nitric oxide (NO), activated leukocyte cell adhesion molecule (ALCAM), and lipoprotein-associated phospholipase (LpPLA2) levels. From the peripheral venous blood, we analyzed B-type natriuretic peptide (BNP) level at baseline and at 1 day after RFCA. Cardiac enzymes, including cardiac-troponin T, creatine kinase-isoenzyme (MB), and myoglobin, were also measured at 1 day after RFCA.
Transthoracic Echocardiography
All examinations were performed using a commercially available Vivid 7 (GE Medical System, Vingmed, Horten, Norway) ultrasound system. All recorded echocardiograms were collected and analyzed using an offline computer analysis station (Echopac 6.3.4; GE Medical Systems).
All measurements were taken from 3 consecutive cardiac cycles and averaged. The maximal LA volume (LAV) was manually measured using the modified Simpson's method after zooming in on the LA by tracing the endocardial border in the apical 4 and 2 chambers over the cardiac cycle. Each echocardiographic parameter was determined according to the recommendations of the American Society of Echocardiography. 12 Transmitral pulsed-wave Doppler velocities were recorded from the apical 4-chamber view with a 2-mm Doppler sample placed between tips of the mitral leaflets. Early (E) and late (A) wave velocities and the E/A ratio were assessed from the mitral inflow profile. Pulsed-wave tissue Doppler imaging was obtained from the apical 4-chamber view. A 2-mm sample volume was placed at the septal and lateral mitral annulus. Systolic (S′), early diastolic (E′), and late diastolic (A′) velocities were measured, and the E/E′ ratio was calculated.
Measurement of Index of Microcirculatory Resistance
All patients with AF underwent routine coronary angiography using the Judkins technique on digitalized coronary angiography equipment (FD-10, Philips Healthcare, Best, The Netherlands). After coronary angiography, a coronary pressure wire (Radi Medical Systems, Uppsala, Sweden) was calibrated outside the body, equalized to the guiding catheter pressure with the sensor positioned at the ostium of the guiding catheter, and then advanced to distal of the left anterior descending coronary artery. The IMR is defined as the distal coronary pressure divided by the inverse of the simultaneously measured thermodilution-derived hyperemic mean transit time (hTmn), or more simply, distal coronary pressure multiplied by the hTmn (mm Hg/s or units [U]). 10 The mean transit time was measured at rest and during hyperemia by methods described previously. 10, 13 Briefly, with commercially available software (Radi Medical Systems), the shaft of the pressure wire can act as a proximal thermistor by detecting changes in temperature-dependent electric resistance. The sensor near the tip of the wire simultaneously measures pressure and temperature and can thereby act as a distal thermistor. The transit time of room temperature saline injected down a coronary artery can be determined using a thermodilution technique. 14 Three injections of saline (3 mL, room temperature) were administered to the coronary artery, and the baseline mean transit time was measured. Intravenous adenosine (140 mg/kg per minute) was then administered to induce steady-state maximal hyperemia; 3 more injections of saline (3 mL, room temperature) were given, and the hTmn was measured. Simultaneous measurements of mean distal coronary pressure (Pd, by pressure wire) were also made in the resting and maximal hyperemic states.
Blood Sampling and Analysis
In all subjects, a blood sample was obtained from the coronary sinus just before and after RFCA for analysis of NO, ALCAM, LpPLA2, and hs-CRP levels. These values were used as indices for endothelial function and inflammatory substances. Blood samples were drawn into ice-chilled tubes containing ethylene diaminetetraacetic acid and were immediately centrifuged at 3000 rpm for 20 minutes. All samples were frozen at −80°C until assay. The samples were batched together for assay and processed by a technician blinded to all subject information.
NO was measured using a colorimetric NO assay kit (Oxford Biomedical Research, Rochester Hills, MI), and data were expressed in micromoles per liter (μmol/L). Plasma ALCAM was quantified by an enzyme-linked immunoassay (ELISA) performed in duplicate samples using commercially available matched antibodies (R&D Systems, Minneapolis, MN), and data were expressed as nanograms per milliliter (ng/mL). LpPLA2 was measured in plasma aliquots using an ELISA (PLAC test; diaDexus Inc, San Francisco, CA), and data were expressed in ng/mL. An ELISA (Alpha Diagnostic International, San Antonio, TX) was used to measure hs-CRP in milligrams per liter (mg/L).
Blood samples were also obtained from a peripheral vein at 1 day after RFCA for analyses of cardiac-troponin T, creatine kinase-MB, myoglobin, and BNP levels. Cardiac-troponin T, creatine kinase-MB, myoglobin, and BNP were analyzed on a Stratus CS analyzer (Dade Behring, Germany), using commercially available test materials.
Ablation Procedure
Before RFCA, transesophageal echocardiography and multislice computerized tomography were performed in all subjects. Intracardiac ECG was recorded using a PruckaCardioLab electrophysiology system (General Electric Health Care System, Inc, Milwaukee, WI), and a 3D electroanatomical mapping system (NavX; St. Jude Medical Inc, Minnetonka, MN) was used in all subjects.
After double transseptal puncture, systemic anticoagulation was achieved with intravenous heparin to maintain an activated clotting time between 300 and 350 s. After the 3D geometry of LA and pulmonary veins (PVs) was determined using the NavX mapping system and then merged with volume-rendered multislice computerized tomography imaging, all PVs were mapped with a decapolar circular catheter (Lasso; Biosense Webster, Diamond Bar, CA). An open-irrigation, 3.5-mm tip-deflectable catheter (Celsius; BiosenseWebster) was used for mapping and ablation. Radiofrequency energy was delivered at a maximum power output of 25 to 30 W, a flow rate of 17 to 30 mL/min, and a maximum temperature of 48°C. The end point for each individual application at a given site was either total voltage abatement or current application of up to 40 s with adequate tissue contact and power delivery. A stepwise ablation procedure was used in all patients with AF, regardless of AF type. Initially, all patients underwent wide circumferential PV isolation. For patients who remained in sinus rhythm after circumferential PV isolation, an inducibility test with 10 mA pacing was performed in the high right atrium or coronary sinus using a pacing cycle length of 180 ms with a 1:1 capture. If induced AF was sustained for >10 minutes without isoproterenol infusion or patients who remained in AF after circumferential PV isolation, an additional ablation of complex fractionated atrial electrogram sites on both atria was completed until the termination of AF was observed. A complex fractionated atrial electrogram was defined as an electrogram with a fractionated interval between 50 and 120 ms, displayed by color map on the NavX geometry. In cases where AF converted to organized atrial flutter (AFL), a local activation time map was created during stable AFL and was displayed on the NavX geometry. Several rounds of radiofrequency energy were then delivered to the critical isthmus or foci until AFL termination was observed. In patients with PeAF and induced typical AFL, a cavotricuspid isthmus line was created and the bidirectional block was confirmed by a differential pacing maneuver. If subjects remained in AF up to 5 hours after beginning RFCA, we performed direct current cardioversion to restore sinus rhythm. Before the end of procedure, all ablated PVs were revisited and then PVs with evidence of reconnection were reisolated.
Follow-up
If no complications arose during the procedure, anticoagulation therapy with warfarin was initiated without any antiarrhythmic medications. All subjects were prospectively followed for AF recurrence after RFCA at monthly outpatient clinic visits. Subjects also underwent 48-hour Holter monitoring at 1 and 3 months post-RFCA. An ECG was performed during every visit and at any time that the subject reported palpitations. In addition, a nurse practitioner questioned each subject by telephone at 2-week intervals, and all subjects were instructed to call whenever they experienced symptoms. Any patient with documented AF or AFL during the follow-up period was diagnosed as having a clinical arrhythmia recurrence and was treated with antiarrhythmic medications.
Statistical Analysis
All continuous variables were expressed as either the mean±SD or the median (25th, 75th percentiles range), depending on the distribution. For continuous data, statistical differences were evaluated using Student t test or the Mann-Whitney U test, depending on the data distribution. The paired t test or Wilcoxon signed-rank test was used for analyzing the changes of parameters between just before and after RFCA, depending on the data distribution. Nonparametric tests were used in analyzing hs-CRP, BNP, and triglyceride because they had no normal distribution. Categorical variables were presented as frequencies (percent) and were analyzed using the Fisher exact test. Changes in the E/E′ ratio from baseline at 1 day, 1 month, and 3 months after RFCA were analyzed using 2-way repeated measures analysis.
To determine whether any of the variables were independently related to increasing IMR, multivariate logistic regression analysis of variables with a P value of <0.10 in univariate analysis was performed. The area under the receiver-operating characteristic curve was used to evaluate the discrimination of prediction of recurrence and then to derive sensitivity and specificity values for each cutoff value. All statistical analyses were conducted using SPSS statistical software, version 13.0 (SPSS Inc, Chicago, IL), and statistical significance was set at P≤0.05 in 2-sided tests.
Results
Baseline Characteristics
Of the 136 patients with AF initially enrolled, 58 patients who had AF within 24 hours before the examination, 24 patients who presented significant coronary artery stenosis during coronary angiography, and 5 patients in whom attempts to advance the pressure wire to distal of left anterior descending coronary artery failed were excluded from this analysis. Control group was patient with supraventricular tachycardia. AF indicates atrial fibrillation; ALCAM, activated leukocyte cell adhesion molecule; BNP, B-type natriuretic peptide; CK-MB, creatine kinase-MB; hs-CRP, high-sensitivity C-reactive protein; IMR, index of microvascular resistance; LpPLA2, lipoprotein-associated phospholipase; NO, nitric oxide; PAF, paroxysmal AF; PeAF, persistent AF; and RFCA, radiofrequency catheter ablation.
*Values shown are differences between before and after RFCA. Hs-CRP and BNP were expressed as median (25th to 75th percentiles range). †P value was calculated using Mann-Whitney U test.
The final study group then included 49 subjects with AF (PAF, n=25 and PeAF, n=24) and 34 controls. All AF subjects were followed until the end of the study period (3 months after RFCA). AF recurred in 1 (PeAF=1) patient at 1 day, 9 (PAF=2, PeAF=7) patients during the first month, and 4 (PAF=1, PeAF=3) patients during 3 months after RFCA. There were no procedure-related complications in all subjects. The baseline demographic and echocardiographic parameters of study participants are summarized in Table 1 . Men were more common, and LA size was larger in AF subjects compared with controls.
Of patients with AF, the IMR was increased after RFCA in 36 subjects, and there were no significant differences in baseline characteristics between 2 groups. Changes of biomarker levels and IMR before and after RFCA are summarized in Table 2 . Compared with controls, pre-BNP, pre-and post-RFCA ALCAM, and post-RFCA hs-CRP and BNP were much higher in AF subjects. Changes of hs-CRP, NO, ALCAM, and LpPLA2 between just before and after RFCA were significantly greater in AF group. However, there were no significant differences between PAF and PeAF. Compared with subjects who did not have increasing IMR (n=13), post-RFCA NO was significantly lower and post-RFCA ALCAM was significantly higher in subjects with increasing IMR. Changes of ALCAM and LpPLA2 between just before and after RFCA were significantly greater in subjects with increasing IMR. However, there was no statistical difference in pre-and post-RFCA BNP level in AF subjects. The cumulative energy application (eg, ablation time and cardiac enzymes after RFCA) was not different between the 2 groups. Figure 1B) , ALCAM (2.21±1.20 ng/mL versus 2.77±0.92 ng/mL; P=0.016), and LpPLA2 (268.2±79.9 ng/mL versus 309.6±77.7 ng/mL; P=0.001) were significantly increased after RFCA compared with those before RFCA ( Figure 2 ). NO was significantly decreased after RFCA in all AF subjects, irrespective of early recurrence (Figure 2A ). However, there were no significant differences in levels of NO, ALCAM, and LpPLA2 in control group between before and after RFCA (Figure 2) . Figure 3 illustrates changes in the E/E′ ratio from baseline to values at 1 day, 1 month, and 3 months after RFCA. In subjects with increasing IMR, the E/E′ ratio was significantly increased at 1 day after RFCA, decreased at 1 month, and returned to the baseline level at 3 months after RFCA. However, in subjects without increasing IMR, the E/E′ did not change significantly. Table 3 shows the logistic regression analysis for variables related to an increase in IMR after RFCA for AF. Changes in ALCAM and LpPLA2 between just before and after RFCA were independently related to increasing IMR after adjustment for LAV, the E-wave, and the serum myoglobin. Table 4 showed that PeAF, LAV, myoglobin, ablation time, total procedure time, and the change in IMR between just before and after RFCA were significantly associated with early recurrence after RFCA for AF. However, in multivariate analysis, PeAF, LAV, and the change in IMR were independent predictors for early recurrence after AF ablation. Figure 4 shows the receiver-operating characteristic curve of the IMR change for prediction of early recurrence after RFCA for AF. Using a cutoff value of 9.3 mm Hg/s in IMR change, the sensitivity was 46.7% (95% confidence interval, 0.248-0.699) and specificity was 91.2% (95% confidence interval, 0.770-0.970).
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Discussion
The noteworthy findings of the present study are as follows: (1) nonischemic, iatrogenic myocardial injury through RFCA provoked coronary microvascular dysfunction, which may be caused by proinflammatory substances (ALCAM, LpPLA2) released from damaged myocardial endothelium into systemic circulation; (2) LV diastolic dysfunction, assessed from the E/E′ ratio and possibly attributable to increased IMR, was reversible within 3 months after RFCA; (3) increasing IMR as well as PeAF and LAV was independently associated with arrhythmia recurrence in the first 3 months after RFCA for AF; and (4) the increase in IMR of >9.3 mm Hg/s may present a new parameter for identifying patients at high risk for early recurrence after AF ablation.
Although RFCA has been considered as an effective and curative treatment option for AF, early recurrence within 1 to 3 months after AF ablation is reported to occur in 35% to 65% of patients treated with RFCA. [15] [16] [17] Although arrhythmia recurrence during this early period is regarded as a prominent factor in long-term AF recurrence, ≈50% of the patients who have early recurrence remain free from AF in the absence of any further treatments, including antiarrhythmic drugs during the long-term follow-up. 15 Therefore, both clinical trial results and the experience of many investigators indicate that early recurrence does not necessarily represent procedural failure. This transient increase in risk may hypothetically be explained as a "the blanking period," after RFCA. Several mechanisms likely account for the heightened vulnerability during the blanking period include local inflammation in the damaged myocardium, heightened adrenergic tone, and changes in medications and in fluid and electrolyte balance. 2, 4, 5 We found that in a substantial number of patients, LV diastolic function decreased initially but recovered within 3 months after RFCA (Figure 3 ). This transient LV diastolic dysfunction was only observed in patients with increasing IMR. This result might indicate that impairment of myocardial blood supply caused by coronary microvascular dysfunction makes an important contribution to LV diastolic dysfunction. Furthermore, because LV diastolic dysfunction plays a prominent role in creating an arrhythmogenic substrate, 18, 19 our original findings present a plausible mechanism for early recurrence during the blanking period.
Several substances related to endothelial dysfunction and inflammatory response are released into systemic circulation. NO, produced by endothelial cells, maintains the endothelium in a constant state of vasodilatation and may act to attenuate proinflammatory response and inhibit adhesion molecule expression. 20 Circulating adhesion molecules reflect an inflammatory interaction between endothelial cells and leukocytes and are strongly associated with the adverse outcome among patients with coronary artery disease, acute coronary syndromes, and heart failure. 21 In addition, circulating adhesion molecules contribute to microvascular dysfunction as inflammatory mediators. 22 Through binding to the capillary lumen, ALCAM facilitates migration of leukocytes through capillary walls into surrounding tissues. Resulting cellular and intracellular edema may lead to blood vessel congestion and impaired coronary perfusion. 23 LpPLA2 circulates in association with low-density lipoprotein and promotes vascular inflammation through hydrolysis of sn-2 fatty acids of oxidized phospholipids to oxidized fatty acid and lysophosphadidylcholine. 24 These particles amplify the inflammatory response and may further increase LpPLA2 levels. 25 We demonstrated that changes in ALCAM and LpPLA2 between baseline and after RFCA for AF were independently associated with increasing IMR (Table 3) , and the increase in IMR between just before and after RFCA was independent predictor for early recurrence after AF ablation (Table 4 ). These findings suggest that circulating proinflammatory substances released from damaged myocardial cells contributed to the coronary microvascular dysfunction resulted in arrhythmia recurrence during the blanking period. However, we observed increasing IMR in only ≈3 of 4 patients who underwent AF ablation. In addition, increase in ALCAM and LpPLA2 after RFCA was only observed in AF patients with early recurrence, whereas there were no significant changes in patients without recurrence and controls ( Figure 2 ). Furthermore, our study demonstrated that the amount of myocardial damage, which represented with ablation time, creatine kinase-MB, troponin-T, and myoglobin, was not independently related to early recurrence after RFCA for AF (Table 4 ). These results suggest that profound activation of circulating adhesion molecules may be influenced by other factors rather than nonischemic myocardial injury itself or catheter manipulation in the heart.
Limitations
The first limitation of our study is the intentional selection of patients who had sinus rhythm at the time of enrollment so as to minimize beat-to-beat variations from AF itself and potential effects of these variations on circulating inflammatory substances and coronary microvascular endothelial function. Because we may thereby have excluded patients with profound LA remodeling, our results may not be extrapolated to patients with long-term PeAF or permanent AF. Second, we measured BNP levels at baseline and after RFCA, and there were no significant differences in study populations, irrespective of AF type and the change in IMR. Because we used the irrigation ablation catheter in all patients with AF, change of volume status for a short period of time may influence BNP levels in our results. 26 Therefore, we suggested that tissue Doppler study might be more appropriate modality to assess LV diastolic function in patient undergoing RFCA for AF. Third, we proposed that, using a cutoff value of 9.3 mm Hg/s, the increase in IMR may present an identifying marker for high-risk patients who are likely to experience early recurrence during the blanking period after RFCA for AF. However, the clinical relevance may be limited because the measurement of IMR is not always applicable in clinical practice. Fourth, sample size was relatively small. For the purpose of a greater clinical perspective, a large-scale, multicenter study would be needed. Finally, we could not provide serial assessments for IMR from coronary artery and proinflammatory biomarkers from coronary sinus during the follow-up period in patients with AF and in controls for ethical reasons. Therefore, we cannot conclude that the reversal of LV diastolic dysfunction is directly associated with improvement of coronary microvascular function and exactly distinguish between a direct and a by-stander role of proinflammatory substances in pathophysiology of early recurrence. Further investigations are indicated, using a simple, reproducible, and noninvasive technique to assess coronary microvascular function.
Conclusions
We have shown for the first time that nonischemic, iatrogenic myocardial damage induced by RFCA may evoke coronary microvascular endothelial dysfunction through increasing systemic levels of adhesion molecules; these proinflammatory substances may, in turn, contribute to transient LV diastolic dysfunction. This phenomenon may represent a potential mechanism for increased risk of early recurrence during the blanking period after AF ablation. We propose that measurement of coronary microvascular dysfunction may serve as a useful criterion to identify patients who are likely to experience early recurrence after AF ablation. Furthermore, pharmacological inhibitors of adhesion molecule expression may potentially prevent early recurrence after RFCA for AF.
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